The Pharma Data

DECEMBER 23, 2020

Joseph Kim , President and CEO of INOVIO, said, “We are very pleased to share peer-reviewed Phase 1 clinical data for INO-4800 published in The Lancet’s EClinicalMedicine , and are grateful for the support of all participants and investigator staff involved in the clinical trial.” . PLYMOUTH MEETING, Pa. ,

DNA 40

DNA Vaccination Vaccine Immune Response 40

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

APRIL 8, 2024

Outstanding Achievement Award Pfizer Chairman and CEO Dr Albert Bourla received the 2024 AACR Outstanding Achievement Award for Service to Cancer Science and Medicine on behalf of Pfizer during the Opening Ceremony. This dual action triggers cell death across a spectrum of cancer types, including those resistant to current treatments.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

XTalks

JANUARY 26, 2024

This technology, which allows for precise editing of DNA at specific locations, has been a major focus in the field due to its potential to directly target and modify cancer-causing genes. Personalized medicine: One of the most exciting prospects of CRISPR/Cas9 in oncology is its contribution to personalized medicine.

Research 118

Research Gene Editing Gene Genetics 118

pharmaphorum

APRIL 7, 2021

billion-plus alliance with UK biotech Artios Pharma to develop precision medicines for cancer. The new deal with Artios allows Novartis to tap into Artios’ DDR technology platform, which focuses on compounds that can prevent cancer cells from repairing damage to their DNA via a process called synthetic lethality.

DNA 52

DNA Licensing Licensing Gene Therapy 52

Drug Discovery World

APRIL 14, 2023

Carl H June, MD, FAACR – Lifetime Achievement in Cancer Research June, a Fellow of the AACR Academy, is the Richard W Vague Professor in Immunotherapy, Director of the Center for Cellular Immunotherapies, and Director of the Parker Institute for Cancer Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania.

Genetics 52

Genetics Research Medicine Clinical Research 52

XTalks

JANUARY 19, 2024

Radiobiological and Clinical Considerations from CRO and Emerging Biotech Radiopharmaceuticals are medicinal formulations containing radioisotopes that are used in the field of nuclear medicine primarily for the diagnosis and treatment of various diseases, particularly cancer. There have been more than $1.7

DNA 66

DNA Radiology FDA Approval Development 66